OncoMatch/Clinical Trials/NCT03492671
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Is NCT03492671 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Gemcitabine 1000 mg and nab-paclitaxel for pancreas adenocarcinoma.
Treatment: Gemcitabine 1000 mg · nab-paclitaxel — The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage LOCALIZED, POTENTIALLY RESECTABLE
Excluded: Stage BORDERLINE RESECTABLE, IV
Localized, potentially resectable tumors. Patient has borderline resectable or metastatic disease [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
anc ≥ 1,500 cells/mm3; platelets ≥ 100,000 cells/mm3
Kidney function
serum creatinine ≤ 2 x uln
Liver function
serum bilirubin ≤ 1.5 x uln; alt ≤ 5 x uln; ast ≤ 5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loma Linda University Health · Loma Linda, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify